Introduction
Since the discovery of p53 in 1979 (Lane et al., 1979; DeLeo et al., 1979; Linzer et al., 1979) ; it has surfaced as a most important tumor suppressor protein central to regulation of cell cycle, apoptosis, DNA repair, senescence, and angiogenesis (Vousden et al., 2002; Fridman et al., 2003; Teodor et al., 2007) . The prominent role of p53 is reflected in nearly 50% cases of malignancies wherein p53 gene is either mutated or under expressed (Feki et al., 2004 , Srivatanakul et al., 2004 Xu et al., 2012 , Tian et al., 2013 . However, the pioneering studies by Oliner et al. (1992) provided a convincing evidence of involvement of other regulatory proteins that encourages abnormal cell division. Involvement of MDM2 (Murine Double Minute 2) as an ancillary protein in sarcomas (Oliner et al., 1992 , Yang et al., 2014 avenues in oncological research which offered a clue in understanding the pathophysiological rationale behind the cancers wherein wild type status of p53 was retained. MDM2 gene is known to be transcribed by p53 itself (Momand et al., 1992; Jun Liu et al, 2011) , once expressed, MDM 2 binds to the p53 transactivation domain and inhibits its transcriptional activity (Momand et al., 1992; Chen et al., 1993) and exports p53 out of the nucleus. The event is followed by proteasome-mediated degradation of p53 that makes it degradation and rendering it inaccessible to the target genes (Freedman et al., 1998; Haupt et al., 1997) . The process can be thought of feedback loop mechanism wherein both p53 and MDM2 is maintained in the basal levels in the normal cell (Wu et al., 1993) . However, in certain malignancies the over expression of MDM2 renders p53 inactive which involves synergistic MDM2-p53 interactions (Momand et al., 1998) .
Approaches in disruption of MDM2-p53 interactions have now surfaced as an important therapeutic strategy in resurrection of p53 function. Highly potent and specific small-molecule inhibitors with desirable pharmaceutical properties to inhibit MDM2-p53 interactions such as Nutlin-3 and MI-219 (Shangary et al., 2008) are now available. Studies using these inhibitors in preclinical models have already provided strong evidence that targeting the MDM2-p53 interaction using small-molecule inhibitors is a promising cancer therapeutic approach Patton et al., 2006; Tovar et al., 2006; Sarek et al., 2007) . Nevertheless, as every drug suffers setbacks, Nutlin-3 and MI-219 in spite being potential inhibitors haves hown limited tumor volume reduction (Ray et al., 2012 , Stakleff et al., 2012 . Therefore in the view of above, through virtual screening approaches, we sought to identify a novel compound as a substitute to the customary drugs anticipated having higher affinity against MDM2 protein and possibly having commendable potential in disrupting MDM-p53 interactions.
Materials and Methods

Selection of inhibitors and structure similarity search
Nutlin3A and RG7112 belonging to compound class of cis-imidazoline, MI219 of spiro-oxindole class and benzodiazepine derived TDP 665759 served as query molecules for shape similarity search.
Structure similarity search was performed by NCBI's Pubchem search with a threshold of 95%. All the similar molecules were screened with Lipinski filters.
Ligand receptor docking
Molecular docking program Molegro Virtual Docker (MVD, 2010.4.0.0) which includes highly efficient PLP (Chanda Sinha et al., 2015) and MolDock scoring function (Yang et al., 2004) provided flexible platform for molecular docking (Bandaru et al., 2014) . The optimized structures of Nutilin3A, MI-69, MI-217, RG7112 and TDP 7115 were docked into the p53 binding cleft of MDM2 protein. Docking parameters were set to 0.20 Å as grid resolution, maximum iteration of 1500 and maximum population size of 50. Energy minimization and hydrogen bonds were optimized after the docking. Simplex evolution was set at maximum steps of 300 with neighborhood distance factor of 1. Binding affinity and interactions of inhibitor with protein was evaluated on the basis of the internal ES (Electrostatic Interaction), internal hydrogen bond interactions and sp2-sp2 torsions. Post docked ligand-receptor complex energy was minimized using Nelder Mead Simplex Minimization (using non-grid force field and H bond directionality) (Nelder et al., 1965) .
Protein-protein docking studies
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain was retrieved from Protein Databank with (PDB accession number: 1YCR). Protein -Protein docking was executed through object recognition and image segmentation algorithm embedded in Patchdock server (Schneidman et al., 2005) . Default parameter was set as clustering RMSD at 4.0.
Lipinksi filters toxicity screening and bioactivity prediction of compounds
All the similar compounds retrieved were screened for its drug ability by lipinksi filters. The toxicity screening was achieved by using LAZAR toxicity prediction server (Maunz et al., 2013) . Biological activity score of the ligands was predicted using Molinspiration webserver ( © Molinspiration Cheminformatics, 2014). LC 50 was predicted using T.E.S.T. Version 4.1 (2012, U.S. Environmental Protection Agency) software. The complete ADMET properties was calculated using admetSAR (Cheng et al., 2012) .
Solvent accessible surface area (SASA) and interface property calculation
Solvent accessible surface area of the complexes were calculated by GETAREA server (Ahmad et al., 2004) , protein interfaces calculated by Aquaprot (Reichmann et al., 2008) and interface property was calculated using 2P2I inspector (Basse et al., 2013) online server.
Results and Discussion
Evident from rerank scores, all the akin compounds identified against parent compound had higher binding affinity against MDM2 protein in comparison to parent compounds. Further, compound PubCid: 71132874 akin to MI 219 showed highest affinity against the MDM2 receptor amongst the compounds undertaken in this study. The docking scores of top selected compounds belonging to each lead compound are provided in Table 1 .
The compounds were further screened for their in silico ADMET profile, compound PubCid: 11952782 DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9 
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akin to TDP 665759 and compound 77819398 akin to RG 7112 showed toxicity being mutagenic and carcinogenic respectively. The ADMET profile of the compounds is represented in Table 2 .
As evident from protein-protein docking studies, the MDM2-p53 interactions are efficiently inhibited in presence of inhibitors as compared to ligand free MDM2, thus implying there occurs a declined MDM2-p53 interactions in presence of inhibitors. It is interesting to note that, except for compound PubCid:77819398 akin to showed showed 1.14 folds better inhibitory potential than its parent compounds Nutlin 3A. The patch dock scores (protein-protein docking scores) of MDM2-p53 interaction in presence of inhibitors and their respective akin is shown in Table 3 . 
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The MDM2-p53 docking results were further complemented by interface property calculations. Interface properties of MDM2-p53 complex in presence and absence of inhibitors is shown in Table 4 . From extensive interface properties calculated it is quite apparent that all the similar compounds had well inhibitory potential than their respective parent compound. As mentioned afore, PubCid :68870345-a Nutlin 3A akin compound was superior among the undertaken compounds in preventing the MDM-p53 interactions (as revealed from patch dock scores),the interface properties calculations further asserts this observation. The concurrence between patch dock results and MDM2-P53 interface property calculation is supported by the fact that the total interface area in MDM-p53 complex was 2.1 folds declined in presence of compound PubCid : 68870345 compared to the complex harboring its parent compound Nutlin 3A.Further the comparative analysis of the number of surface and buried atoms of the MDM2 -p53 complexes has unveiled that PubCid:68870345bound MDM2 -p53 complex had considerable increase in the number of surface atoms and a decrease in buried atoms implying a weak interaction between p53 and MDM2. Likewise, gap index and SASA was highest between MDM2-p53 in presence of PubCid :68870345 indicating it to be the powerful and potential inhibitor undertaken in the existing study. In addition to the analyses, the LC 50 values and bioactiity of the compounds were predicted. The LC 50 values at 96 hour interval were predicted to be least lethal (Table 5 ). In addition the similar compounds identified against their parents show enhanced bioactivity providing a clue for target specificity. Nutlin 3A similar compound had highest inhibitory potential in the present study. There was 1.44 folds increase in the SASA when MDM bound to Nutlin 3A similar to Nutlin 3A bound counterparts (Δ SASA Nutlin 3A sim-Nutlin 3A=2651.98, folds=1.44). In addition, there was considerable decrease of interface area in the interactions involving Nutlin 3A similar (ΔIA Nutlin 3A-Nutlin 3ASim=376, folds=2.16). Further gap volumes testifies the inhibitory potential of Nutlin 3A Similar than any other compound undertaken in the study (Δ GVNutlin 3A Sim-Nutlin 3A=618.7, folds=1.51) Solvent accessible surface area of the MDM2 -p53 complex in the presence of the parent and respective akin with that of the ligand free MDM2-P53 complex, Nutlin 3A akin bound MDM2-P53 complex showed highest total solvent accessibility surface area which gives a clue towards decreased MDM2 -P53 interaction. It is also imperative to note that the total solvent accessibility surface area of Nutlin 3A akin bound MDM2-P53 complex has increased by 1.45 folds when compared to the Nutlin3A bound MDM2-P53 complex.
Owing to superior inhibitory potential of Nutlin 3A PubCid: 68870345 similar it was further mapped for its pharmacophoric properties. figure 5 .
In conclusion, the together with molecular docking analysis, protein-protein patch docking, interface property and SASA analysis has put forth that the Nutlin 3A akin compound demonstrated and brought about the weakest interaction between MDM2 and p53, thereby making p53 available for carrying out its tumor suppressing actions in the cells.
MDM2 and p53 interaction is a primary mechanism for inhibition of the p53 function in cancers retaining wildtype p53, targeting the MDM2-p53 interaction by small molecules to reactivate p53 has emerged as a promising new cancer therapeutic strategy. In the present study the potential of Cis-imidazoline derivative (CID 68870345) -a compound akin to Nutlin 3A had appreciable potential to inhibit MDM2-p53 interactions than any compound in the study. Extensive analysis using molecular docking analysis, protein-protein patch docking, interface property and SASA analysis testifies superior inhibitory potential of Nutlin 3A akin compound; however the in vitro and in vivo experimental correlates are required to complement 
